Erasca eliminates chief operating officer role, effective November 2026
The company said the move is tied to a restructuring of leadership duties around its RAS-targeting drug programs.
Erasca, Inc. disclosed in an 8-K filing dated October 15, 2026 that it is reorganizing senior management duties. The company said it made the decision to restructure leadership oversight to help advance development and potential commercialization work on its RAS-targeting drug programs.1
As part of that change, duties currently handled by the chief operating officer are being redistributed to other leaders at the company, a move intended to simplify its internal reporting lines.1
As a result, Nicholas (Nik) Chetwyn, Ph.D., who holds the Chief Operating Officer title, will leave the company, with his employment ending on November 2, 2026.1
The filing was signed by Ebun Garner, Chief Legal Officer, on October 15, 2026. The document does not specify who will absorb Chetwyn's responsibilities or detail any severance terms tied to his departure.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.